The head of Eli Lilly & Company India told a workshop that Indian biotech and pharmaceutical companies are the driving forces behind India's outsourcing business and said the nation stands to benefit from a group of situations if it can capitalize on them. Chairman and Managing Director Rajiv Gulati said Indian companies need to capitalize on the momentum built by U.S. generics makers, initiatives in generic biology, transition of patent laws, a focus on basic research and the practice of pharma outsourcing itself.

Related Summaries